Imiloxan

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C14H16N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZJ56PS1DWK, chemically known as 1h-imidazole, 2-((2,3-dihydro-1,4-benzodioxin-2-yl)methyl)-1-ethyl-, (7r-(7alpha,8beta,10beta))- but generally known as imiloxan, which bears US NIH Compound Identifier 133621. European Medicines Agency schedules Imiloxan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08149MIG. The term IMILOXAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). IMILOXAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule imiloxan under HS 29349990 and SITC 51579. As of Q4 2014, IMILOXAN remains the US FDA Preferred Term for this commodity. Imiloxan bears US NLM identifiers UMLS ID C0063395 and NCI Concept Code C83792. SMILES: O1C(CC2N(CC)CCN2)COC2C1CCCC2.